Safety and Efficacy of QAX576 in Adults With Moderate Persistent Allergic Asthma

Status:
Withdrawn

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

This study will evaluate the safety and efficacy of QAX576 against asthma attacks in adults with moderate persistent allergic asthma

Phase 1/Phase 2

Novartis